Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-981 (Subasumstat) plus Pembrolizumab in Advanced or Metastatic Solid Tumors
2020-004325-23Phase 2Completed
- Sponsor
- Takeda
- Start
- Nov 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and subasumstat in Nonhematologic neoplasms and cancer, sponsored by Takeda. Primary endpoint: Phase 1b primary endpoints. Started Nov 2022; status: completed.
02
Drugs
pembrolizumabsubasumstat
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on 2020-004325-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004325-23.